单次立体定向放射外科对比手术切除联合立体定向放射外科治疗大体积脑转移瘤:多中心分析
该多中心回顾性研究纳入2005至2013年两家机构213例患者共223个大体积脑转移瘤(≥4 cm3),比较单次SRS alone与手术切除联合SRS的颅内结局和总生存。结果显示手术联合SRS组局部复发率显著更低(1年局部复发率20.5% vs 36.7%,P=.007),总生存显著更高(2年OS率38.9% vs 19.8%,P=.01),但术后SRS组放射性坏死率最高(1年22.6%,P<.001)。
要点
- 大体积脑转移瘤(≥4 cm3)手术联合SRS较单次SRS alone显著降低1年局部复发率(20.5% vs 36.7%)。
- 手术联合SRS组2年总生存率显著高于SRS alone组(38.9% vs 19.8%)。
- 术后SRS组1年放射性坏死率最高(22.6%),高于术前SRS(5%)和SRS alone(12.3%)。
核心结论
- 对于大体积脑转移瘤患者,肉眼全切除联合SRS与单次SRS alone相比,局部复发率显著降低,总生存显著提高。
- 术后SRS与最高的放射性坏死率相关。
- 手术切除联合SRS可能改善有限数目大体积脑转移瘤患者的结局,但需进一步研究。
研究设计与样本
- 多中心回顾性研究,纳入2005至2013年两家机构连续治疗的213例患者共223个大体积脑转移瘤(≥4 cm3)。
- 66个(30%)病灶接受单次SRS alone,157个(70%)接受手术联合SRS(63个术前SRS,94个术后SRS)。
- 采用多因素校正分析和倾向性评分匹配分析验证结果。
主要发现
- 手术联合SRS组1年局部复发率显著低于SRS alone组(20.5% vs 36.7%,P=.007)。
- 手术联合SRS组2年总生存率显著高于SRS alone组(38.9% vs 19.8%,P=.01)。
- 术后SRS组1年放射性坏死率显著高于术前SRS组和SRS alone组(22.6% vs 5%和12.3%,P<.001)。
- 两组间病灶体积中位数(5.9 cm3 vs 9.6 cm3,P<.001)、脑转移瘤数目中位数(1.5 vs 1,P=.002)、SRS剂量中位数(18 Gy vs 15 Gy,P<.001)及既往全脑放疗比例(33% vs 5%,P<.001)存在显著差异。
关键数值与推荐
- 大体积脑转移瘤定义为研究前≥4 cm3(直径2 cm)。
- 单次SRS alone组中位SRS剂量18 Gy,手术联合SRS组中位SRS剂量15 Gy(P<.001)。
临床怎么用
- 对于有限数目的大体积脑转移瘤,可考虑肉眼全切除联合SRS以降低局部复发并可能改善总生存。
- 选择术后SRS时需警惕放射性坏死风险升高,术前SRS或单次SRS alone的放射性坏死率相对较低。
局限性
- 回顾性研究设计,存在选择偏倚。
- 两组在病灶体积、脑转移瘤数目、SRS剂量及既往全脑放疗比例上存在显著差异。
- 样本来自两家机构,结论需进一步研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Stereotactic radiosurgery (SRS) dose is limited by brain metastasis (BM) size. The study goal was to retrospectively determine whether there is a benefit for intracranial outcomes and overall survival (OS) for gross total resection with single-fraction SRS versus SRS alone for patients with large BMs. METHODS AND MATERIALS: A large BM was defined as ≥4 cm3 (2 cm in diameter) prior to the study. We reviewed the records of consecutive patients treated with single-fraction SRS alone or surgery with preoperative or postoperative SRS between 2005 and 2013 from 2 institutions. RESULTS: Overall, 213 patients with 223 treated large BMs were included; 66 BMs (30%) were treated with SRS alone and 157 (70%) with surgery and SRS (63 preoperatively and 94 postoperatively). The groups (SRS vs surgery and SRS) were well balanced except regarding lesion volume (median, 5.9 cm3 vs 9.6 cm3; P<.001), median number of BMs (1.5 vs 1, P=.002), median SRS dose (18 Gy vs 15 Gy, P<.001), and prior whole-brain radiation therapy (33% vs 5%, P<.001). The local recurrence (LR) rate was significantly lower with surgery and SRS (1-year LR rate, 36.7% vs 20.5%; P=.007). There was no difference in radiation necrosis (RN) by resection status, but there was a significantly increased RN rate with postoperative SRS versus with preoperative SRS and with SRS alone (1-year RN rate, 22.6% vs 5% and 12.3%, respectively; P<.001). OS was significantly higher with surgery and SRS (2-year OS rate, 38.9% vs 19.8%; P=.01). Both multivariate adjusted analyses and propensity score-matched analyses demonstrated similar results. CONCLUSIONS: In this retrospective study, gross total resection with SRS was associated with significantly reduced LR compared with SRS alone for patients with large BMs. Postoperative SRS was associated with the highest rate of RN. Surgical resection with SRS may improve outcomes in patients with a limited number of large BMs compared with SRS alone. Further studies are warranted.
引用
- Prabhu RS, Press RH, Patel KR, et al. Single-Fraction Stereotactic Radiosurgery (SRS) Alone Versus Surgical Resection and SRS for Large Brain Metastases: A Multi-institutional Analysis. Int J Radiat Oncol Biol Phys. 2017. PMID: 28871997. doi:10.1016/j.ijrobp.2017.04.006
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。